Regulation of polyisoprenylated methylated protein methyl esterase by polyunsaturated fatty acids and prostaglandins

Polyisoprenylation is a set of secondary modifications involving proteins whose aberrant activities are implicated in cancers and degenerative disorders. The last step of the pathway involves an ester‐forming polyisoprenylated protein methyl transferase‐ and hydrolytic polyisoprenylated methylated protein methyl esterase (PMPMEase)‐catalyzed reactions. Omega‐3 and omega‐6 PUFAs have been linked with antitumorigeneis and tumorigenesis, respectively. PUFAs are structurally similar to the polyisoprenyl groups and may interfere with polyisoprenylated protein metabolism. It was hypothesized that PUFAs may be more potent inhibitors of PMPMEase than their more polar oxidative metabolites, the prostaglandins. As such, the relative effects of PUFAs and prostaglandins on PMPMEase could explain the association between cyclooxygenase‐2 (COX‐2) expression in tumors, the chemopreventive effects of the non‐steroidal anti‐inflammatory (NSAIDs) COX‐2 inhibitors and PUFAs. PUFAs such as AA, EPA, and DHA inhibited PMPMEase activity with K_i values of 0.12–3.7 µM. The most potent prostaglandin was 63‐fold less potent than AA. The PUFAs were also more effective at inducing neuroblastoma cell death at physiologically equivalent concentrations. The lost PMPMEase activity in AA‐treated degenerating cells was restored by incubating the lysates with COX‐1 or COX‐2. PUFAs may thus be physiological regulators of cell growth and could owe these effects to PMPMEase inhibition. Practical applications: Some PUFAs have been widely reported to have anticancer benefits. However, the molecular mechanisms for these effects are not well understood. The findings in the current paper appear to suggest that inhibition of PMPMEase may underlie their effects. They also imply that the expression of COX‐2 in various tumors may serve to convert the PUFAs into significantly less inhibitory prostaglandins. From these findings, AA and the other PUFAs, rather than being substrates for the synthesis of tumorigenic agents may actually contribute in suppressing cell proliferation. This being congruent with the lower cancer risks associated with long term use of anti‐inflammatory agents, the practical implications will likely include the nutritional and/or therapeutic management of cancer with the goal of maintaining suitable levels of the fatty acids in tissues.